-
Go 6983 Links PKC to Cell-Fate Assays
2026-09-18
Go 6983 is a pan-PKC inhibitor for dissecting kinase-dependent signaling in cancer, EMT, and metabolism-focused cell-fate assays. This article connects PKC perturbation with the WDR36–glycolysis mechanism reported in human blastoids while clearly separating established evidence from testable hypotheses.
-
GSK2606414: Practical PERK Inhibitor Workflows
2026-09-18
GSK2606414 provides a selective pharmacological route to test whether PERK connects ER stress with inflammatory cell death. This workflow translates nucleus pulposus cell findings into practical dose, timing, orthogonal readout, and troubleshooting strategies for ER stress research, cancer research, and related disease models.
-
Psoralen-Induced Cholestasis via ERK1/2 Activation
2026-09-17
Chen and colleagues show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through estrogen-related signaling and ERK1/2 activation. The study connects disrupted bile-acid synthesis and transport with ERK phosphorylation inhibition rescue, positioning ERK1/2 as a mechanistically testable target in phytoestrogen-associated cholestasis.
-
JNK-IN-7 for MAPK and Apoptosis Assays
2026-09-17
JNK-IN-7 is a selective JNK inhibitor for separating c-Jun phosphorylation, inflammatory signaling, and apoptosis in cell-based experiments. Its covalent kinase engagement and concentration-dependent Pellino 1 activity make it especially useful for mechanistic studies of pathogen-triggered innate immune responses.
-
Dual-Action Inhibitors Reshape p38α Dephosphorylation
2026-09-16
The reference preprint shows that kinase inhibitors can do more than block p38α catalytic activity: selected compounds also expose the activation-loop phosphothreonine to the WIP1 phosphatase. Structural and biochemical data support a conformation-directed strategy that could improve the potency and specificity of kinase pathway modulation, while requiring further validation in cellular and disease models.
-
SB 431542 ALK5 Inhibitor Workflow Guide
2026-09-16
Use SB 431542 to resolve TGF-β receptor biology in primary trophoblast–immune co-cultures, glioma assays, and anti-tumor immunology research. This workflow emphasizes receptor selectivity, rapid Smad2 readouts, donor-aware controls, and practical troubleshooting rather than treating one concentration as universally predictive.
-
SD 169: Practical p38 MAPK Assay Workflows
2026-09-15
SD 169 (indole-5-carboxamide) helps researchers connect selective p38α/β inhibition with practical readouts in inflammatory, diabetes, apoptosis, and nerve-repair models. This workflow-focused guide covers stock preparation, pathway validation, cross-domain applications, and troubleshooting without overstating model-specific results.
-
Y-27632 and the Gut–Brain Translation Gap
2026-09-15
A mechanistic and strategic analysis of how Y-27632 dihydrochloride can help translational researchers test cytoskeletal contributions to gut-to-brain α-synuclein transfer, while separating established ROCK biology from an emerging, unvalidated hypothesis.
-
Busulfan Beyond Depletion: A Translational Lens
2026-09-14
Busulfan is more than a DNA-damaging reagent: it is a controllable perturbation for studying senescence, germ-cell loss, and the limits of regenerative claims. This article connects its molecular behavior with dual-recombinase lineage tracing to provide practical guidance for translational experimental design.
-
Fucoidan and Chemotherapy-Induced Steatohepatitis
2026-09-14
A 2026 study identifies intestinal barrier failure, lipopolysaccharide translocation, and hepatic neutrophil extracellular traps as a connected mechanism in irinotecan-induced steatohepatitis. It further shows that Fucoidan can preserve tight-junction integrity, partially moderate microbiota disruption, and reduce NET-associated liver inflammation in mice, providing a mechanistic framework for studying chemotherapy-related liver injury.
-
Moret et al. on Optimized Small-Molecule Libraries
2026-09-13
Moret et al. developed a data-driven framework for comparing and designing small-molecule libraries using target coverage, binding selectivity, cellular phenotypes, chemical structure, clinical-development status, and user preferences. The resulting LSP-OptimalKinase and LSP-MoA collections show how computational library design can improve biological coverage while limiting redundant or overlapping off-target activity.
-
CRC Organoids Program Distinct Treg Cells
2026-09-12
This preprint presents a co-culture model showing that colorectal cancer organoids can directly drive CD4+ T-cell differentiation into a distinct, highly suppressive Treg population through TGFβ-dependent mechanisms. The system links organoid-induced Treg transcriptional programs with tumor-associated Treg features and unfavorable patient outcomes, providing a tractable platform for mechanistic and therapeutic studies.
-
LY364947: Reframing EMT Control in Translational Research
2026-09-11
TGF-β-driven epithelial plasticity remains a major challenge in cancer, fibrosis, and tissue injury models. This thought-leadership article positions LY364947 as a receptor-proximal tool for testing whether direct TGF-β type I receptor blockade can clarify EMT biology, complement insights from CDK4/6 and BET inhibition, and improve translational study design without overstating preclinical evidence.
-
IGF2BP2 Links m6A to Ovarian Cancer Glycolysis
2026-09-11
The reference study combines single-cell and bulk transcriptomics with genetic, metabolic, flow-cytometric, and RIP-seq analyses to identify IGF2BP2 as a malignant epithelial cell-associated m6A reader in ovarian cancer. Its findings connect IGF2BP2-dependent RNA stabilization with cell-cycle progression, apoptosis resistance, and glycolytic activity, while pharmacological inhibition supports the feasibility of targeting this regulatory axis.
-
SP600125: From JNK Mechanism to Translation Strategy
2026-09-10
SP600125 is more than a conventional pathway probe: it can help translational researchers connect JNK-dependent stress signaling with inflammation, apoptosis, cytokine regulation, and the broader control of protein synthesis. This article outlines how to use the compound rigorously while leveraging a CDK4–4E-BP1 study to frame a testable, but not yet proven, bridge between kinase signaling and translational control.